Slingshot members are tracking this corporate initiative:
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases for $1.2B
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Apr 04, 2016 Projected Implementation: Q1, 2016 Relevance Tracked Until: Q2, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Acetyl-coa Carboxlyase, Acc, Nash, Liver Diseases, Ndi-010976, Fast Track Designation, Metabolic Dysfunction, Hepatocellular Injury, Acc Inhibitors, Aberrant Lipid-derived Signaling, Steatosis, Fibrosis, Inflammation